Literature DB >> 30472793

Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.

N Woltsche1, N Pichler2, I Wolf2, N Di Meo3, I Zalaudek3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30472793     DOI： 10.1111/jdv.15367

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: A single-center study and a new dedicated therapeutic protocol.

Authors:  Vincenzo De Giorgi; Luciana Trane; Giulia Pieretti; Nicola Santoro; Flavia Silvestri; Federico Venturi; Federica Scarfì; Vincenza Maio; Giuseppe Spinelli; Silvia Scoccianti; Laura Guerrini; Daniela Massi; Cinzia Mazzini; Laura Doni
Journal:  Dermatol Reports       Date:  2021-08-05

Review 2.  Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives.

Authors:  Markus V Heppt; Christoffer Gebhardt; Jessica C Hassel; Mareike Alter; Ralf Gutzmer; Ulrike Leiter; Carola Berking
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

3.  Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).

Authors:  Alessia Villani; Matteo Megna; Gabriella Fabbrocini; Milena Cappello; Maria Antonietta Luciano; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-10

4.  Management of patients with melanoma and non-melanoma skin cancers in the coronavirus disease 2019 era.

Authors:  Claudio Conforti; Nicola di Meo; Roberta Giuffrida; Iris Zalaudek
Journal:  Chin Med J (Engl)       Date:  2020-09-05       Impact factor: 2.628
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.